anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There are many drugs which may increase or decrease phenytoin levels or which phenytoin may affect. Serum level determinations for phenytoin are especially helpful when possible drug interactions are suspected. The most commonly occurring drug interactions are listed below:

  1. Drugs which may increase phenytoin serum levels include: acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, ticlopidine, tolbutamide, trazodone.
  2. Drugs which may decrease phenytoin levels include: carbamazepine, chronic alcohol abuse, reserpine, and sucralfate. Moban® brand of molindone hydrochloride contains calcium ions which interfere with the absorption of phenytoin. Ingestion times of phenytoin and antacid preparations containing calcium should be staggered in patients with low serum phenytoin levels to prevent absorption problems.
  3. Drugs which may either increase or decrease phenytoin serum levels include: phenobarbital, sodium valproate, and valproic acid. Similarly, the effect of phenytoin on phenobarbital, valproic acid, and sodium valproate serum levels is unpredictable.
  4. Although not a true drug interaction, tricyclic antidepressants may precipitate seizures in susceptible patients and phenytoin dosage may need to be adjusted.
  5. Drugs whose efficacy is impaired by phenytoin include: corticosteroids, coumarin anticoagulants, digitoxin, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, theophylline, vitamin D.



### Drug Enteral Feeding/Nutritional Preparations Interaction

Literature reports suggest that patients who have received enteral feeding preparations and/or related nutritional supplements have lower than expected phenytoin plasma levels. It is therefore suggested that phenytoin not be administered concomitantly with an enteral feeding preparation. More frequent serum phenytoin level monitoring may be necessary in these patients.
Experienced lower-limb amputees that will be tested with a 4-week interval. No intervention. This group will be matched to the group of experienced lower-limb amputees.
PURPOSE OF REVIEW: To summarize the evidence and clinical implications of weight and body composition changes during midlife in women and provide an overview of weight gain prevention and management in this population.
RECENT FINDINGS: Aging-related changes such as decreased energy expenditure and physical activity are important culprits for weight gain in midlife women. The hormonal changes of menopause also influence body adiposity distribution and increase central adiposity. These body changes can have health consequences including the development of cardiometabolic diseases, osteoarthritis, cancer, worsening in cognition, mental health, and menopause symptoms. Midlife women experience changes related to aging, menopause, and lifestyle which favor weight gain. Clinical practice should focus on early counseling and anticipatory guidance on the importance of dietary changes and physical activity to attenuate this phenomenon. Future research should focus on the longitudinal relationship between weight trends in midlife and health consequences and mortality.
A second generation of antineoplaston therapies with markedly improved antineoplastic activity is disclosed. Among others, members of the antineoplaston family include phenylacetate (PN), 3-phenylacetyl-amino-2,6, piperidinedione (CN), and hydrolysis derivatives of CN: phenylacetylglutamine (PG) and iso-phenylacetylglutamine (Iso-PG). In part, these increases in antineoplastic activity result from large increases in the transport of antineoplaston compositions into cells. Importantly and unexpectedly these increases in antineoplastic activity also result from the capacity of the drug delivery system to direct antineoplaston compounds intracellular trafficking to intracellular binding sites influencing cell viability and proliferation. Liposomal formulations of antineoplaston compositions increase in vitro antineoplastic activity by a factor of 750 to 1500 as compared to administration of antineoplaston compounds given without liposomal formulations. In addition, these liposomal formulations enhanced cellular uptake of antineoplaston compounds form 30 to more that 80 fold. Liposomal formulations were also found to increase intracellular levels of the antineoplaston CN(3-phenylacetyl-amino-2,6, piperidinedione) by directing CN to intracellular binding sites that influence cell viability and proliferation and block its hydrolysis. Under conditions where free CN has no antineoplastic activity, liposomally formulated CN can produce essentially complete and relatively long-lasting blockade of cell growth. Cell growth was found to be restored as intracellular levels of bound CN decrease to undetectable levels.
PURPOSE: A Hizikia fusiforme extract having an activity of suppressing TRAIL-resistant cancer cells is provided to induce TRAIL-mediated apoptosis and to uses in preventing and treating cancer. CONSTITUTION: A pharmaceutical composition of anticancer activity contains Hizikia fusiforme extract and TRAIL(tumor necrosis factor-related apoptosis-inducing ligand) as an active ingredient. The Hizikia fusiforme extract is Hizikia fusiforme ethyl alcohol extract(EAHF). The Hizikia fusiforme ethyl alcohol extract is obtained by drying Hizikia fusiforme and extracting with ethyl alcohol. The composition has activity specifically in TRAIL-resistant cancer cells. The TRAIL-resistant cancer cell is human gastric adenocarcinoma(AGS) cells.
The extract compsn. used as an anticancer drug is produced by (a) mixing a root of an akebia with a defatted starch of a croton genus seed, (b) extracting the mixture at 60˜80deg. C for 10˜15hrs, (c) concentrating the extract, saturating the concentrated soln. and filtering it to separate a filtered soln. and a residue, (d) adding an organic solvent i.e. chloroform or hexane to the extracted soln., and shaking the mixture to remove the organic solvent, (e) extracting the aq. soln. with an ethanol or a hexane, (f) adding a talc to the aq. soln. to obtain a purified soln., and (g) filtering the soln., and freeze drying it.
The first 20 eligible patients will be consented to undergo intracervical 18F-FDG injection during a dynamic PET/CT scan. Study enrollment will occur in the clinic during the visit in which they are consented for surgery. Recruited patients will undergo 18F-FDG-guided PET imaging on the day of their scheduled staging surgery. The experimental PET/CT is anticipated to take 2 hours. The second stage of accrual will replace PET/CT with PET/MRI imaging. In every other aspect, patients will receive standard peri- and postoperative care.
In every surgical procedure, there is a need to close the incision that was made. Current methods for incision closure include stitching, gluing and stapling. Some of these methods are time consuming, have potential for infection and may leave a significant scar. The bioWeld1 technology suggests a new approach for incision closure. It is a novel medical device that consists of a Chitosan film and the BioWeld1 plasma ejecting device. The Chitosan film is intended to be applied to the skin incision, while the BioWeld1device is used for welding the Chitosan to the skin by means of cold plasma technology.
Botulinum Toxin (Botox) has been used for many years in the treatment of oculofacial dystonias such as blepharospasm and hemifacial spasm. It has also gained widespread use for cosmetic purposes. The efficacy and duration of its effect is not constant amongst all patients. Some patient respond very well, while others have no clinical benefit or the clinical benefit does not last as long as expected. Zinc is known to be an important co-factor in the molecular effects of Botox. The investigators hypothesize that one of the many factors that may contribute to the variability in the response to Botox may be the level of Zinc available within the neuromuscular junction of those patients. The investigators plan to to test whether or not giving patients supplemental Zinc with their Botox injections would help improve the magnitude and duration of the intended clinical effect.
This is a randomized (study medication assigned to participants by chance), double-blind (neither the researchers nor the participants know what treatment the participant is receiving), parallel-group, placebo-controlled (an inactive substance; a pretend treatment \[with no drug in it\] that is compared in a clinical trial with a drug to test if the drug has a real effect) study. The study consists of Screening Phase (maximum of 42 days prior to Week 0), Treatment Phase (Week 0-12) and Follow-up Phase (up to Week 16). Participants will be randomly assigned to receive JNJ-38518168 (3 milligram \[mg\] or 30 mg or 60 mg) or placebo once daily. The initial group of the participants will be randomized to either JNJ-38518168 30 mg or placebo. The dose assignments for the subsequent participants will depend on the results of up to 2 interim analyses. Efficacy will be primarily assessed by percentage of participants who achieve a Psoriasis Area and Severity Index (PASI) 75 response at Week 12. Participants' safety will be monitored throughout the study.
PURPOSE:A cosmetic that contains a specific amount of an ester made from hydroxybenzoic acid and an alcohol of 6 or more carbon atoms, thus being effective for improving the cornification of skins. CONSTITUTION:An ester made from a hydroxybenzoic acid and an alcohol of 6 or more carbon atoms, such as hexyl p-hydroxybenzoate, lauryl p-hydroxybenzoate, cetyl p-hydroxybenzoate, cholesteryl p-hydroxybenzoate, cycloartenyl p-hydroxybenzoate, is added by 0.05-20pts.wt. per 100pts. of the cosmetic. The ester positively prevents the cornification of skins such as roughening, chapping or dandruffing. It is added to cream, milk rotion, cleansing, lip stick, shampoo, rinse, tonic or hair-dressing.
ADA Recognition maintains the standard that a follow up to diabetes education must occur from 3-6 month post education. This one phone call will be made by the diabetes educator. The intervention is the diabetes educator making a phone call to the patient to ask how they are doing.
The poster-sized (18x24 inches) commitment letter, written at the 8th grade reading-level and displayed in English and Spanish, emphasize clinician commitment to guidelines for appropriate antibiotic prescribing and explain why antibiotics are not appropriate in many cases. These letters, featuring clinician photographs and signatures, are displayed in clinician exam rooms for a 16-week period.
Symptomatic patients with cervical changes objectified by endovaginal ultrasound of the cervix with length \<20mm. Asymptomatic patients with a history of premature delivery or late miscarriage and cervical changes objectified by endovaginal ultrasound of the cervix with length \<20mm.
As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other ranibizumab products may be misleading.

The pre-treatment incidence of immunoreactivity to ranibizumab was 0%-5% across treatment groups. After monthly dosing with ranibizumab for 6 to 24 months, antibodies to ranibizumab were detected in approximately 1%-9% of patients.

The clinical significance of immunoreactivity to ranibizumab products are unclear at this time. Among neovascular AMD patients with the highest levels of immunoreactivity, some were noted to have iritis or vitritis.

Intraocular inflammation was not observed in patients with RVO patients with the highest levels of immunoreactivity.
Hepatitis b virus (HBV) related acute-on-chronic liver failure (ACLF) is a serious condition with high mortality rate in China. But there still lacks of effective therapies in treatment of HBV related ACLF, except liver transplantation. Non-bioartificial liver support system treatments may be effective due to previous clinical data. Plasma exchange (PE) and double plasma molecular adsorption system (DPMAS) are two common ways in clinical practice. This study is to investigate the clinical efficacy and safety of combination treatment of DPMAS and low volume PE in patients with HBV related ACLF. This study will be completed in 6 medical center. Two hundred patients with HBV related ACLF enrolled in this study are divided into trial group (DPMAS, low volume PE, and comprehensive internal medical treatment) and control group (comprehensive internal medical treatment). Symptoms, signs, laboratory tests results, adverse events, mortality rates are recorded from treatment baseline to 12 weeks.
PURPOSE: A composition containing camphene for preventing or treating metabolic disorder is provided to reduce visceral fat, total cholesterol, and neutral fat and to prevent or treat obesity, hyperlipidemia, or fatty liver. CONSTITUTION: A composition for preventing or treating metabolic diseases contains camphene as an active ingredient. The metabolic diseases include obesity, dyslipidemia, fatty liver or insulin resistant syndrome. The dyslipidemia is hyperlipidemia. A pharmaceutical composition for preventing or treating obesity, dyslipidemia, fatty liver, or insulin resistant syndrome contains therapeutically active amount of the composition and pharmaceutically acceptable carrier. Camphene is derived from a plant.
In PCSA group of patients, remifentanil was given by bolus PCSA using a pump (Pain Management Provider, Abbott Laboratories and Eczacibasi-Baxter, Ireland). In PCSA group of patients, remifentanil infusion was at a dose of 0.05 µg/kg, a bolus dose of 0.1 μg/kg with a lock-out time of three minutes.
The invention provides cyclic carboxamide compounds and analogues thereof of Formula (I) and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula (I) are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.
The present invention is a radix astragali kidney supplementing nutritional agent. The radix astragali kidney supplementing nutritional agent comprises the following components in parts by weight: 10-15 parts of radix astragali, 5-10 parts of ginsengs, 5-10 parts of fructus ligustri lucidi, 5-8 parts of mulberries, 5-8 parts of fructus schisandrae chinensis, 6-10 parts of semen cuscutae, 10-25 parts of rhizoma anemarrhenae, 10-16 parts of smoked plums, 8-15 parts of gekko gecko, 3-5 parts of radix aconiti carmichaeli, 5-10 parts of herba taxilli, 10-15 parts of radix dipsaci asperoidis, and 15-20 parts of carapax et plastrum testudinis. The nutritional agent can effectively regulate and supplement human body and enable the body kidney function to obtain an effective recovery without taking medicines. The radix astragali and ginsengs have functions of supplementing and tonifying kidney essence and qi. In addition, the semen cuscutae and the radix aconiti carmichaeli have functions of warming and tonifying kidney-yang, the semen cuscutae and the radix aconiti carmichaeli have relative strong tendon and bone strengthening, and back pain removing effects. The carapax et plastrum testudinis and the rhizoma anemarrhenae have functions of nourishing yin and supplementing yang, and clearing and relieving heat deficiency. In addition, the smoked plums and the gekko gecko have very good effects for kidney dysfunction in qi holding.
A fluid composition suitable for coating tablets consists essentially of about 10 to 25 parts by weight of a "water-soluble" wax as hereinafter defined and about 2 to 10 parts by weight of a polyvinylpyrrolidone-vinyl acetate copolymer per 100 ml. of the composition and a non-aqueous solvent for said wax and said copolymer.  The waxes are polyethylene glycols of melting point of at least 50 DEG C., glyceryl monostearate and diglycol stearate, or mixtures thereof.  The copolymers contain 30-70, and preferably 60% of vinylpyrrolidone and 70 to 30% and preferably 40% of vinyl acetate.  Optional ingredients are (a) dyes, lakes and pigments (b) water-insoluble waxes such as beeswax, lanolin, stearic acid, cocoa butter and cetyl alcohol (c) plasticizers such as castor oil, mineral oil, corn oil, sesame oil and propylene glycol, alone or in admixture with a drying oil such as soybean oil (d) surface-active ingredients such as polyoxyethylene sorbitan derivatives and sulphated fatty alcohols and (e) cellulose acetate.  Specifications 762,229 and 764,342 are referred to.ALSO:A coated solid medicament has the coating material in the form of a physiologically acceptable composition consisting essentially of a water permeable combination of a water-soluble or water-dispersible wax (A) and a polyvinylpyrrolidone vinyl acetate copolymer (B).  The waxes are polyethylene glycols of melting point at least 50 DEG  C., glyceryl monostearate and diglycol stearate, or mixtures thereof.  The copolymers contain 30-70, and preferably 60% of polyvinylpyrrolidone and 70 to 30%, and preferably 40% of vinyl acetate.  Optional ingredients are (a) dyes, lakes and pigments, (b) water-insoluble waxes such as beeswax, lanolin, stearic acid, cocoa butter and cetyl alcohol (C); (c) plasticizers such as castor oil, mineral oil, corn oil, sesame oil and propylene glycol, alone or in admixture with a drying oil such as soybean oil (D); (d) surface-active agents such as polyoxyethylene sorbitan derivatives and sulphated fatty alcohols; and (e) an antisticking agent which is cellulose acetate.  The compositions contain 10 to 25 grms. of (A), 2 to 10 grms. of (B), not more than 1 grm. of (C) and not more than 2 grms. of (D) per 100 ml. of the fluid composition which is prepared by dissolving the components in a non-aqueous solvent such as acetone, ethanol or mixtures thereof.  The finished coat contains 50-92% of (A), 8 to 50% of (B) and not more than 5% of the optional components. Specifications 762,229 and 764,342 are referred to.
PCT No. PCT/US92/09662 Sec. 371 Date Nov. 10, 1994 Sec. 102(e) Date Nov. 10, 1994 PCT Filed Nov. 12, 1992 PCT Pub. No. WO93/10228 PCT Pub. Date May 27, 1993This invention provides isolated nucleic acid molecules encoding a mammalian glycine transporter, isolated nucleic acid molecules encoding a human glycine transporter, isolated proteins which are mammalian glycine transporter proteins, isolated proteins which are human glycine transporter proteins, vectors comprising isolated nucleic acid molecules encoding a mammalian or a human glycine transporter, mammalian cells comprising such vectors, antibodies directed to a mammalian glycine transporter, antibodies directed to a human glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding mammalian glycine transporter, nucleic acid probes useful for detecting nucleic acid encoding human glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a mammalian glycine transporter, antisense oligonucleotides complementary to any sequences of a nucleic acid molecule which encodes a human glycine transporter, pharmaceutical compounds related to mammalian glycine transporter, pharmaceutical compounds related to human glycine transporter and nonhuman transgenic animals which express DNA encoding a normal or a mutant mammalian or human glycine transporter. This invention also provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with mammalian glycine transporter. This invention further provides methods for determining ligand binding, detecting expression, drug screening, and treatments for alleviating abnormalities associated with human glycine transporter.
575,827. Clarifying foul liquids. TRIGGS, W. W. (Dorr Co.) Aug. 23, 1944, No. 16091. [Classes 46 and 111] Apparatus for the clarification of polluted liquids comprises a tank having partitioning means the lower edge of which is spaced from the bottom of the tank, so that the tank is divided into two communicating compartments, each compartment having means for the supply and withdrawal of liquid, means being provided for delivering into the second compartment liquid that has been withdrawn from the first compartment and submitted to an additional treatment, and means being provided for withdrawing sediment from the bottom of the tank. In the construction indicated in Figs. 1 and 2, a tank 10 is divided into two compartments 22, 23 by a partition 19 which terminates above the bottom of the tank to leave a space for passage of an endless conveyer 40 provided with scrapers 47 for delivering sediment to a sump 13. Liquid to be treated enters compartment 22 by a feed pipe 6 and is distributed by a launder 25 and baffle 26. At the other end of the compartment is a launder 32 from which liquid flows through pipe 73 to a biologic trickling filter 70. Liquid also flows to the filter through pipe 75 from the outlet'37 of the compartment 23. The filtered liquid is pumped through pipe 82 and valve-controlled pipes 83,84 to the feed pipe 6 and to a launder 30 of the compartment 23. Scum is removed through a slotted trough 58 provided with an adjusting handle 60. In a modification the filter is above the level of the top of the tank and the pump supplies the liquid to the filter. Fig. 7 shows an arrangement in which two filters are used. Liquid from launder 30 is led by a pipe 106 to a well 107 from which it is pumped through pipes 108, 110 to a filter 100. The filtered liquid flows through pipes 101, 102, 103, pipe 103 communicating through pipe 104 with a well 105 from which liquid is pumped to the filter 120. The filtered liquid flows to launder 32. The quantity of liquid supplied to the launder 32 may be larger than that overflowing past the weir 36 whereby a back flow of liquid occurs along the bottom of the tank from compartment 23 to compartment 22, and this facilitates the work of the scrapers 47 on the endless conveyer 40.
At Visit 2, participants will receive repeated oral inhalations of PT027 to treat acute airway obstruction induced by a repeated airway challenge, followed by a washout period of 10-14 days. At Visit 3, participants will receive repeated oral inhalations of PT007 to treat acute airway obstruction induced by a repeated airway challenge.